WHAT IS CLAIMED IS:

1. Use of a composition comprising antigen presenting cells in the manufacture of a medicament for treating a tumor in a subject in need thereof wherein the antigen presenting cells are obtained from a species that is different than the subject.

2. The use of claim 1, wherein the tumor is a solid tumor, and the medicament is formulated for intratumoral injection into the tumor of the subject.

3. The use of any one of the preceding claims, wherein the antigen presenting cells are obtained from a species that is a swine.

4. The use of any one of the preceding claims, wherein the antigen presenting cells are obtained from a species that is a miniature swine.

5. The use of any one of the preceding claims, wherein the subject is a human.

6. The use of claim 3, wherein the swine is an alpha-1,3 galactosyltransferase-deficient swine.

7. The use of claim 6, wherein the alpha-1,3 galactosyltransferase-deficient swine is a swine leukocyte antigen (SLA)-inbred swine.

8. The use of claim 4, wherein the miniature swine is an alpha-1,3 galactosyltransferase-deficient miniature swine.

9. The use of claim 8, wherein the alpha-1,3 galactosyltransferase-deficient miniature swine is a swine leukocyte antigen (SLA)-inbred swine.

10. The use of any one of the preceding claims, wherein the medicament triggers an immune response specific to the tumor.

11. The use of any one of the preceding claims, wherein the medicament yields an abscopal effect.

12. The use of any one of the preceding claims, wherein the tumor is a solid cancerous tumor.

13. The use of claim 12, wherein the tumor is selected from the group consisting of sarcomas, carcinomas, lymphomas, breast tumors, prostate tumors, head and neck tumors, glioblastomas, bladder tumors, pancreatic tumors, liver tumors, ovarian tumors, colorectal tumors, pulmonary tumors, cutaneous tumors, lymphoid tumors, gastrointestinal tumors, gastrointestinal stromal tumors, cervical tumors, hepatocellular carcinomas, renal cell carcinomas, melanomas, colorectal carcinomas, esophageal carcinomas, brain tumors, kidney tumors, lung tumors (including non-small cell lung cancer), gastric tumors, bile-duct tumors, uterine tumors, and childhood (pediatric) tumors.

14. The use of any one of the preceding claims, wherein the tumor is resistant to treatment to chemotherapy and/or treatment with an immunotherapy.

15. The use of any one of the preceding claims, wherein the antigen presenting cells are derived from one or more swine or miniature swine using a leukapheresis procedure, wherein the leukapheresis procedure generates a leukopak containing peripheral blood mononuclear cells, and the leukopak is further fractionated by counterflow elutriation.

16. The use of any one of the preceding claims, wherein the composition comprising antigen presenting cells is substantially free of pathogens.

17. The use of any one of the preceding claims, wherein the antigen presenting cells are obtained from swine or miniature swine of different genotypes.

18. The use of any one of the preceding claims, wherein the composition comprising antigen presenting cells is to be administered in single or multiple doses.

19. The use of any one of the preceding claims, wherein the composition comprising antigen presenting cells is to be administered *via* an intratumoral injection of at least 1 x 10^6 antigen presenting cells per dose.

20. The use of any one of the preceding claims, wherein the composition comprising antigen presenting cells is to be administered *via* an intratumoral injection of about 1 x 10^6, about 5 x 10^6, about 10 x 10^6, about 15 x 10^6, about 20 x 10^6, about 25 x 10^6, about 30 x 10^6, about 35 x 10^6, about 40 x 10^6, about 45 x 10^6, about 50 x 10^6, about 55 x 10^6, about 60 x 10^6, about 65 x 10^6, about 70 x 10^6, about 75 x 10^6, about 80 x 10^6, about 85 x 10^6, about 90 x 10^6, about 95 x 10^6, about 10 x 10^7, about 15 x 10^7, about 20 x 10^7, about 25 x 10^7, about 30 x 10^7, about 35 x 10^7, about 40 x 10^7, about 45 x 10^7, or about 50 x 10^7 antigen presenting cells per dose.

21. The use of any one of the preceding claims, wherein the antigen presenting cells are substantially mature antigen presenting cells.

22. The use of any one of the preceding claims, wherein the antigen presenting cells are not activated or stimulated.

23. The use of any one of the preceding claims, wherein the composition comprises peripheral blood mononuclear cells (PBMC).

24. The use of any one of the preceding claims, wherein the composition comprises monocytes.

25. The use of any one of the preceding claims, wherein the composition comprises dendritic cells, macrophages, granulocytes, T-cells, B-cells, and/or NK cells.

26. The use of any one of the preceding claims, wherein the composition comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or greater than 95% PBMCs, wherein the PBMCs are mature, immature, or a combination of mature and immature PBMCs.

27. The use of any one of the preceding claims, wherein the composition comprises at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or greater than 95% monocytes, wherein the monocytes are mature, immature, or a combination of mature and immature monocytes.

28. The use of claim 27, wherein the composition comprises a mixture of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or greater than 95% monocytes and dendritic cells, wherein the monocytes and/or dendritic cells in said mixture may be mature, immature, or a combination of mature and immature monocytes and/or dendritic cells.

29. The use of claim 28, wherein the mixture comprises from 10% to 95%, 10% to 90%, 10% to 80%, 10% to 70%, 10% to 60%, 10% to 50%, 10% to 40%, 10% to 30%, 10% to 20%, 20% to 95%, 20% to 90%, 20% to 80%, 20% to 70%, 20% to 60%, 20% to 50%, 20% to 40%, 20% to 30%, 30% to 95%, 30% to 90%, 30% to 80%, 30% to 70%, 30% to 60%, 30% to 50%, 30% to 40%, 40% to 95%, 40% to 90%, 40% to 80%, 40% to 70%, 40% to 60%, 40% to 50%, 50% to 95%, 50% to 90%, 50% to 80%, 50% to 70%, 50% to 60%, 60% to 95%, 60% to 90%, 60% to 80%, 60% to 70%, 70% to 95%, 70% to 90%, 70% to 80%, 80% to 95%, 80% to 90%, 90% to 95%, or greater than 95% monocytes.

30. The use of claim 28, wherein the mixture comprises from 10% to 30%, 35% to 55%, 60% to 80%, or 85% to 95% monocytes.

31. The use of claim 28, wherein the mixture comprises at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or greater than 95% monocytes.

32. The use of claim 28, wherein the mixture comprises from 10% to 95%, 10% to 90%, 10% to 80%, 10% to 70%, 10% to 60%, 10% to 50%, 10% to 40%, 10% to 30%, 10% to 20%, 20% to 95%, 20% to 90%, 20% to 80%, 20% to 70%, 20% to 60%, 20% to 50%, 20% to 40%, 20% to 30%, 30% to 95%, 30% to 90%, 30% to 80%, 30% to 70%, 30% to 60%, 30% to

50%, 30% to 40%, 40% to 95%, 40% to 90%, 40% to 80%, 40% to 70%, 40% to 60%, 40% to 50%, 50% to 95%, 50% to 90%, 50% to 80%, 50% to 70%, 50% to 60%, 60% to 95%, 60% to 90%, 60% to 80%, 60% to 70%, 70% to 95%, 70% to 90%, 70% to 80%, 80% to 95%, 80% to 90%, 90% to 95%, or greater than 95% dendritic cells.

33. The use of claim 28, wherein the mixture comprises from 10% to 30%, 35% to 55%, 60% to 80%, or 85% to 95% dendritic cells.

34. The use of claim 28, wherein the mixture comprises at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or greater than 95% dendritic cells.

35. The use of any one of the preceding claims, wherein the subject is receiving another anti-cancer therapy.

36. The use of claim 35, wherein the other anti-cancer therapy comprises treatment with one or more immune checkpoint inhibitors.

37. The use of claim 35, wherein the other anti-cancer therapy is an anti-CTLA4 therapy, anti-PD1 therapy, anti-PDL1 therapy, anti-LAG-3 therapy, tumor-treating fields (TTFs), cell-based therapy, a tyrosine kinase inhibitor, a VEGF inhibitor, or any combination thereof.

38. The use of claim 35, wherein the other anti-cancer therapy comprises treatment with imatinib, sunitinib, regorafenib, pazopanib, nilotinib, avapritinib, ripretinib, sorafenib, pimitespib, ipilimumab, tremelimumab, nivolumab, pembrolizumab, cemiplimab, atelizumab, avelumab, durvalumab, relatlimab, or any combination thereof.

39. The use of any one of claims 35 to 38, wherein the subject does not respond to the other anti-cancer therapy in the absence of administration of the composition comprising antigen presenting cells.

40. A pharmaceutical composition suitable for intratumoral injection, wherein the pharmaceutical composition comprises antigen presenting cells obtained from one or more swine.